Company Overview of Selecta Biosciences, Inc.
Selecta Biosciences, Inc. is a clinical-stage biotechnology company that develops targeted immunotherapies and vaccines that regulate immune responses to prevent and treat diseases. The company provides synthetic vaccine particles (SVP) therapies that are applied in various therapeutic areas with a focus on the inhibition of immunogenicity for protein therapies, treatment of allergies, and treatment of autoimmune diseases. Its SVP therapies prevent effects of anti-drug antibodies caused by the immunogenicity of biologic drugs in patients. The company develops antigen-specific tolerogenic SVPs to prevent and suppress pro-inflammatory responses against a specific antigen for the inhibition of ...
480 Arsenal Street
Watertown, MA 02472
Founded in 2007
Key Executives for Selecta Biosciences, Inc.
Chief Executive Officer, President and Director
Founder, Vice Chairman and Member of The Scientific Advisory Board
Co-Founder and Co-Chair of the Scientific Advisory Board
Co-Founder, Co-Chair of the Scientific Advisory Board and Director
Vice President of Finance
Compensation as of Fiscal Year 2015.
Selecta Biosciences, Inc. Key Developments
Selecta Biosciences, Inc. Presents at Cantor Fitzgerald's Inaugural Healthcare Conference, Jul-08-2015 02:00 PM
Jun 18 15
Selecta Biosciences, Inc. Presents at Cantor Fitzgerald's Inaugural Healthcare Conference, Jul-08-2015 02:00 PM. Venue: Le Parker Meridien Hotel, 119 W. 56th Street, New York, NY 10019, United States. Speakers: Werner Cautreels, Chief Executive Officer, President and Director.
Selecta Biosciences, Inc. Initiates Phase 1 Clinical Program of SEL-212
Jun 10 15
Selecta Biosciences, Inc. announced that it has initiated a Phase 1 clinical study to assess the safety, pharmacodynamic profile, and immunogenicity of pegsiticase, a component of SEL-212. The product candidate is developed for the indications of refractory and tophaceous gout, which result from elevated levels of uric acid within the body that cause debilitating pain and damage to joints and organs. SEL-212, the lead immunotherapeutic candidate from Selecta's proprietary Synthetic Vaccine Particle (SVP™) Platform, is designed to be the first non-immunogenic version of uricase, an enzyme that metabolizes uric acid. While uricase therapeutics have been demonstrated to be very effective in breaking down uric acid deposits that cause refractory or tophaceous gout, their utility is limited by undesired immune responses in patients, which compromise both efficacy and safety. This Phase 1 clinical study is a single ascending dose multi-center study of pegsiticase in subjects with elevated uric acid levels in order to define safe and effective dose levels for SEL-212. SEL-212 exemplifies Selecta’s approach for deploying its SVP platform to prevent the formation of Anti-Drug Antibodies (ADAs) following repeated treatments with biologics, such as with uricase treatment in severe gout. ADAs are a common problem with other biologic therapies such as enzyme therapy, hemophilia medicines, and novel technologies such as gene therapies and antibody drug conjugates. Application of the SVP platform will yield a pipeline of products with improved therapeutic benefit related to the reduction of unwanted immune responses. Selecta is advancing a series of research and development programs, including a novel Hemophilia A product and novel gene therapy products that enable repeat dosing. By modulating antigen-specific immune responses, the SVP platform can enhance existing therapies and enable novel treatment approaches.
Sanofi Exercises Option on Second Therapeutic Program with Selecta Biosciences to Develop an Antigen-Specific Immunotherapy Based on Synthetic Vaccine Particle Technology
May 13 15
Selecta Biosciences, Inc. announced that, under the terms of an existing strategic global collaboration, Sanofi has exercised its option to an exclusive license to develop an immunotherapy for the treatment of celiac disease. In celiac disease patients, the consumption of gluten-containing food induces harmful immune responses that can lead to abdominal pain and, in most severe cases, intestinal cancer. This new immune tolerance program expands activities within the Sanofi-Selecta collaboration, which is already successfully advancing a novel immunotherapy for a life-threatening food allergy. The products resulting from this collaboration will leverage Selecta’s proprietary Synthetic Vaccine Particle (SVP™) platform, which has unique capabilities to engineer nanoparticles with the structure and composition to produce immune tolerance by attenuating the overactive response to specific antigens. Under the terms of the collaboration, Selecta is eligible to receive research support and several pre-clinical, clinical, regulatory and sales milestones totaling up to $300 million for this new program in celiac disease. Additionally, Selecta is also entitled to up to double digit tiered royalties as percentage of product net sales for any commercialized immunotherapy resulting from these efforts with Sanofi.
Similar Private Companies By Industry
Recent Private Companies Transactions
April 10, 2015
September 30, 2014
August 14, 2014